SG10201914014XA - Non-human animals expressing exogenous terminal deoxynucleotidyltransferase - Google Patents
Non-human animals expressing exogenous terminal deoxynucleotidyltransferaseInfo
- Publication number
- SG10201914014XA SG10201914014XA SG10201914014XA SG10201914014XA SG10201914014XA SG 10201914014X A SG10201914014X A SG 10201914014XA SG 10201914014X A SG10201914014X A SG 10201914014XA SG 10201914014X A SG10201914014X A SG 10201914014XA SG 10201914014X A SG10201914014X A SG 10201914014XA
- Authority
- SG
- Singapore
- Prior art keywords
- human animals
- animals expressing
- expressing exogenous
- terminal deoxynucleotidyltransferase
- exogenous terminal
- Prior art date
Links
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 title 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 title 1
- 241001465754 Metazoa Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07031—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal deoxynucleotidyl transferase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662345524P | 2016-06-03 | 2016-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201914014XA true SG10201914014XA (en) | 2020-03-30 |
Family
ID=59215996
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810757YA SG11201810757YA (en) | 2016-06-03 | 2017-06-02 | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
SG10201914014XA SG10201914014XA (en) | 2016-06-03 | 2017-06-02 | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810757YA SG11201810757YA (en) | 2016-06-03 | 2017-06-02 | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
Country Status (24)
Country | Link |
---|---|
US (2) | US10980221B2 (en) |
EP (2) | EP3462853B1 (en) |
JP (3) | JP7053499B2 (en) |
KR (3) | KR20230156162A (en) |
CN (3) | CN113907043B (en) |
AU (2) | AU2017272337C1 (en) |
BR (1) | BR112018074794A2 (en) |
CA (1) | CA3026088A1 (en) |
CY (1) | CY1126063T1 (en) |
DK (1) | DK3462853T3 (en) |
ES (1) | ES2941810T3 (en) |
FI (1) | FI3462853T3 (en) |
HR (1) | HRP20230497T1 (en) |
HU (1) | HUE061619T2 (en) |
IL (2) | IL263160B2 (en) |
LT (1) | LT3462853T (en) |
MX (3) | MX2018014982A (en) |
PL (1) | PL3462853T3 (en) |
PT (1) | PT3462853T (en) |
RS (1) | RS64216B1 (en) |
RU (1) | RU2753585C2 (en) |
SG (2) | SG11201810757YA (en) |
SI (1) | SI3462853T1 (en) |
WO (1) | WO2017210586A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017210586A1 (en) | 2016-06-03 | 2017-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
SG11202003044SA (en) | 2017-12-05 | 2020-04-29 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
US20190292263A1 (en) * | 2018-03-24 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
CN112566931A (en) * | 2018-06-13 | 2021-03-26 | 儿童医疗中心有限公司 | Methods and compositions relating to high throughput models for antibody discovery and/or optimization |
EP4023059A1 (en) | 2018-06-14 | 2022-07-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
CA3127153A1 (en) * | 2019-02-22 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
CA3136478A1 (en) | 2019-06-05 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
JP2023506760A (en) * | 2019-12-12 | 2023-02-20 | ディーエヌエー スクリプト | Chimeric Terminal Deoxynucleotide Transferases for Template-Free Enzymatic Synthesis of Polynucleotides |
CN111057754B (en) * | 2019-12-27 | 2021-01-12 | 四川省医学科学院.四川省人民医院实验动物研究所 | Method for identifying animal model suitable for HBV research and application |
US20220090060A1 (en) | 2020-09-11 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
AU2021410655A1 (en) | 2020-12-23 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
AU2022249328A1 (en) * | 2021-03-31 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire |
WO2024064860A1 (en) * | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ES2087997T3 (en) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9119338D0 (en) | 1991-09-10 | 1991-10-23 | Inst Of Animal Physiology And | Control of gene expression |
US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US7001614B2 (en) | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
PT942968E (en) | 1996-12-03 | 2008-03-27 | Amgen Fremont Inc | Fully human antibodies that bind egfr |
US7112338B2 (en) | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
MXPA03008454A (en) | 2001-03-22 | 2004-06-30 | Abbott Gmbh & Co Kg | Transgenic animals expressing antibodies specific for genes of interest and uses thereof. |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
JP2006514549A (en) | 2002-12-16 | 2006-05-11 | アメリカ合衆国 | Recombinant vaccine virus expressing IL-15 and method of use thereof |
AU2004208031B2 (en) | 2003-01-28 | 2009-10-08 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
US8218805B2 (en) | 2003-10-11 | 2012-07-10 | Charles Hornback | Wireless speaker system for use with ceiling fans |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
WO2005116072A2 (en) | 2004-05-27 | 2005-12-08 | Weidanz Jon A | Antibodies as t cell receptor mimics, methods of production and uses thereof |
AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
EP1858925A2 (en) | 2005-01-12 | 2007-11-28 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
EP1910418B1 (en) * | 2005-08-03 | 2010-07-21 | Therapeutic Human Polyclonals, Inc. | Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin |
EP1928495A2 (en) | 2005-08-19 | 2008-06-11 | Cerus Corporation | Antibody-mediated enhancement of immune response |
ES2937245T3 (en) | 2005-08-23 | 2023-03-27 | Univ Pennsylvania | RNA containing modified nucleosides and methods of using the same |
CA2638774C (en) | 2006-03-31 | 2015-11-24 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
AU2008259939B2 (en) | 2007-06-01 | 2014-03-13 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
EP2207564B1 (en) | 2007-10-18 | 2016-10-05 | Bavarian Nordic A/S | Use of mva to treat prostate cancer |
US8225343B2 (en) | 2008-01-11 | 2012-07-17 | Sony Computer Entertainment America Llc | Gesture cataloging and recognition |
CN112481300A (en) * | 2008-06-27 | 2021-03-12 | 莫鲁斯股份有限公司 | Non-human mammal producing antibodies |
PL2346994T3 (en) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Knock-in mice for the production of chimeric antibodies |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2011004192A1 (en) | 2009-07-08 | 2011-01-13 | Genome Research Limited | Animal models and therapeutic molecules |
RU2425880C2 (en) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Method of producing transgene mice |
EP3504964A1 (en) | 2009-12-10 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
PL3095871T3 (en) | 2010-02-08 | 2019-10-31 | Regeneron Pharma | Common light chain mouse |
AU2011235569B2 (en) | 2010-03-29 | 2016-06-30 | Zymeworks Bc Inc. | Antibodies with enhanced or suppressed effector function |
KR20210010942A (en) | 2010-03-31 | 2021-01-28 | 아블렉시스, 엘엘씨 | Genetic engineering of non-human animals for the production of chimeric antibodies |
LT2905338T (en) | 2010-06-22 | 2017-12-27 | Regeneron Pharmaceuticals, Inc. | Trangenic mice with a modified endogenous lambda immunoglobulin locus |
CN103025884B (en) | 2010-07-26 | 2015-11-25 | 特里安尼公司 | Transgenic animal and using method |
CN103154255B (en) | 2010-08-02 | 2016-04-06 | 瑞泽恩制药公司 | Manufacture the protein-bonded mouse comprising VL structural domain |
RS59661B2 (en) | 2011-02-25 | 2023-06-30 | Regeneron Pharma | Adam6 mice |
JP5893258B2 (en) | 2011-03-31 | 2016-03-23 | フェリカネットワークス株式会社 | Information processing apparatus and method, and program |
US20130018582A1 (en) | 2011-07-13 | 2013-01-17 | Miller Paul A | Inertial Navigation Common Azimuth Reference Determination System and Method |
HUE055276T2 (en) | 2011-08-05 | 2021-11-29 | Regeneron Pharma | Humanized universal light chain mice |
CA2846322A1 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
DK3216871T3 (en) | 2011-10-17 | 2022-02-21 | Regeneron Pharma | MOUSE WITH RESTRICTED HEAVY IMMUNOGLOBULIN CHAIN |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
IL274914B2 (en) | 2011-10-28 | 2024-02-01 | Regeneron Pharma | Genetically modified t cell receptor mice |
CN113564188A (en) | 2011-10-28 | 2021-10-29 | 瑞泽恩制药公司 | Method for preparing major histocompatibility complex gene modified mouse |
US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
ES2914374T3 (en) | 2011-10-28 | 2022-06-10 | Regeneron Pharma | Genetically modified mice expressing chimeric major histocompatibility complex (MHC) class II molecules |
PL2663575T3 (en) | 2011-10-28 | 2015-03-31 | Regeneron Pharma | Humanized il-6 and il-6 receptor |
BR112014010580B1 (en) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | isolated heteromultimeric fc construct, composition, use of an isolated heteromultimeric fc construct, nucleic acid composition and method for expressing the isolated heteromultimeric fc construct |
US9120662B2 (en) | 2011-11-14 | 2015-09-01 | Susan A. Thomson | Gathering and dispensing scoop with gate valve |
US9547499B2 (en) | 2011-12-09 | 2017-01-17 | Microsoft Technology Licensing, Llc | Device configuration with cached pre-assembled driver state |
SI2883449T1 (en) | 2012-03-16 | 2018-05-31 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
NZ629077A (en) | 2012-03-16 | 2015-12-24 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
CN106318951A (en) * | 2012-03-16 | 2017-01-11 | 瑞泽恩制药公司 | Mice that produce antigen-binding proteins with PH-dependent binding characteristics |
JP5920830B2 (en) | 2012-09-28 | 2016-05-18 | シスメックス株式会社 | Sample preparation device and cell analysis device |
JP6705650B2 (en) | 2012-12-14 | 2020-06-03 | オープン モノクローナル テクノロジー,インコーポレイティド | Polynucleotide encoding rodent antibody having human idiotype and animal containing the same |
CA2897963A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
HUE045478T2 (en) | 2013-02-20 | 2019-12-30 | Regeneron Pharma | Mice expressing humanized t-cell co-receptors |
PL2958937T3 (en) | 2013-02-22 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
SG10201808935WA (en) | 2013-04-16 | 2018-11-29 | Regeneron Pharma | Targeted modification of rat genome |
US9783618B2 (en) * | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
RU2685914C1 (en) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Methods and compositions for genome targeted modification |
BR112016021679A2 (en) | 2014-03-21 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | antigen binding protein, methods of producing an antigen binding protein and identifying one or more antigen binding proteins, hybridoma, nucleic acid, cell, and genetically modified non-human animal. |
KR20210088756A (en) | 2014-03-21 | 2021-07-14 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animals that make single domain binding proteins |
PL3152312T3 (en) | 2014-06-06 | 2020-08-10 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for modifying a targeted locus |
LT3157956T (en) * | 2014-06-19 | 2020-05-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
RS60366B1 (en) | 2014-06-23 | 2020-07-31 | Regeneron Pharma | Nuclease-mediated dna assembly |
SI3161128T1 (en) | 2014-06-26 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
CA2959428A1 (en) * | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
CN113349159B (en) | 2015-04-06 | 2022-11-11 | 瑞泽恩制药公司 | Humanized T cell-mediated immune response in non-human animals |
WO2017210586A1 (en) | 2016-06-03 | 2017-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
-
2017
- 2017-06-02 WO PCT/US2017/035731 patent/WO2017210586A1/en unknown
- 2017-06-02 SG SG11201810757YA patent/SG11201810757YA/en unknown
- 2017-06-02 HR HRP20230497TT patent/HRP20230497T1/en unknown
- 2017-06-02 KR KR1020237037578A patent/KR20230156162A/en not_active Application Discontinuation
- 2017-06-02 HU HUE17733223A patent/HUE061619T2/en unknown
- 2017-06-02 MX MX2018014982A patent/MX2018014982A/en unknown
- 2017-06-02 US US15/612,625 patent/US10980221B2/en active Active
- 2017-06-02 CA CA3026088A patent/CA3026088A1/en active Pending
- 2017-06-02 EP EP17733223.6A patent/EP3462853B1/en active Active
- 2017-06-02 SI SI201731323T patent/SI3462853T1/en unknown
- 2017-06-02 ES ES17733223T patent/ES2941810T3/en active Active
- 2017-06-02 SG SG10201914014XA patent/SG10201914014XA/en unknown
- 2017-06-02 IL IL263160A patent/IL263160B2/en unknown
- 2017-06-02 CN CN202111170801.9A patent/CN113907043B/en active Active
- 2017-06-02 PT PT177332236T patent/PT3462853T/en unknown
- 2017-06-02 KR KR1020227045806A patent/KR102598120B1/en active IP Right Grant
- 2017-06-02 EP EP23151094.2A patent/EP4218408A1/en active Pending
- 2017-06-02 RS RS20230395A patent/RS64216B1/en unknown
- 2017-06-02 BR BR112018074794-7A patent/BR112018074794A2/en unknown
- 2017-06-02 CN CN202310402666.9A patent/CN116458475A/en active Pending
- 2017-06-02 PL PL17733223.6T patent/PL3462853T3/en unknown
- 2017-06-02 DK DK17733223.6T patent/DK3462853T3/en active
- 2017-06-02 RU RU2018144954A patent/RU2753585C2/en active
- 2017-06-02 LT LTEPPCT/US2017/035731T patent/LT3462853T/en unknown
- 2017-06-02 CN CN201780048900.5A patent/CN109640644B/en active Active
- 2017-06-02 KR KR1020187036917A patent/KR102483193B1/en active IP Right Grant
- 2017-06-02 AU AU2017272337A patent/AU2017272337C1/en active Active
- 2017-06-02 FI FIEP17733223.6T patent/FI3462853T3/en active
- 2017-06-02 JP JP2018563156A patent/JP7053499B2/en active Active
-
2018
- 2018-11-30 MX MX2021010351A patent/MX2021010351A/en unknown
- 2018-11-30 MX MX2021010352A patent/MX2021010352A/en unknown
-
2021
- 2021-03-16 US US17/203,398 patent/US20210195877A1/en active Pending
-
2022
- 2022-03-31 JP JP2022058938A patent/JP7274018B2/en active Active
-
2023
- 2023-04-28 JP JP2023074624A patent/JP2023093729A/en active Pending
- 2023-05-31 CY CY20231100257T patent/CY1126063T1/en unknown
- 2023-07-30 IL IL304839A patent/IL304839A/en unknown
-
2024
- 2024-01-31 AU AU2024200577A patent/AU2024200577A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL304839A (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
IL288264A (en) | Genetically modified non-human animals expressing human epo | |
IL247524A0 (en) | Non-human animals that make single domain binding proteins | |
HK1221370A2 (en) | Animal litter | |
PL3053430T3 (en) | Baler | |
PL3262921T3 (en) | Baler | |
HK1258506A1 (en) | Non-human animals having an engineered angptl8 gene | |
HUP1500195A2 (en) | Fodder supplementary additive | |
GB201419207D0 (en) | Animal halter | |
GB201521121D0 (en) | An animal feeder | |
GB2533164B (en) | Animal shelter | |
ZAA201701890S (en) | Beehives | |
GB2561708B (en) | An animal drinker | |
GB201705590D0 (en) | An animal feeder | |
TWM533524U (en) | Improved hurdle structure | |
GB201601653D0 (en) | An animal lead | |
GB201510837D0 (en) | Zoo etc animals | |
PL3075239T3 (en) | Animal shelter | |
GB201510157D0 (en) | Improved animal model | |
GB201903081D0 (en) | Animal shelter | |
GB201417682D0 (en) | Baler with automated ejection of bales | |
GB201502107D0 (en) | Improvements in fishing bait | |
TWM490130U (en) | Micro-connector terminal structure improvement | |
GB201417113D0 (en) | Animal husbandry | |
AU355562S (en) | Animal toy |